
Atea Pharmaceuticals, Inc.: updates and filings
Price
$3.96
November 20, 2026Market cap $316M
What Ploutos Investor adds for Atea Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Nov 9, 2026Material agreement entered, new material financial obligationForm8-K
- Oct 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jun 22, 2026Shareholder voteForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Feb 9, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 8, 2026Results of operationsForm8-K
- Dec 5, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 12, 2025Results of operationsForm8-K
- Aug 7, 2025Shares registered for employeesFormS-8
- Aug 7, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Aug 7, 2025Results of operationsForm8-K
- Aug 6, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Nov 9, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Oct 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jun 22, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Feb 9, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 8, 2026 | 8-K | Results of operations | Document |
| Dec 5, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 12, 2025 | 8-K | Results of operations | Document |
| Aug 7, 2025 | S-8 | Shares registered for employees | Document |
| Aug 7, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Aug 7, 2025 | 8-K | Results of operations | Document |
| Aug 6, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 11, 2013.
The full analysis
What do Atea Pharmaceuticals's filings show?
The filings are where every one of Atea Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.